CENTESSA PHARMACEUTICALS (F:260) — Market Cap & Net Worth
Market Cap & Net Worth: CENTESSA PHARMACEUTICALS (260)
CENTESSA PHARMACEUTICALS (F:260) has a market capitalization of $4.54 Billion (€3.88 Billion) as of May 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #3817 globally and #680 in its home market, demonstrating a 0.61% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CENTESSA PHARMACEUTICALS's stock price €33.20 by its total outstanding shares 147819929 (147.82 Million).
CENTESSA PHARMACEUTICALS Market Cap History: 2021 to 2026
CENTESSA PHARMACEUTICALS's market capitalization history from 2021 to 2026. Data shows growth from $1.70 Billion to $5.74 Billion (13.57% CAGR).
CENTESSA PHARMACEUTICALS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CENTESSA PHARMACEUTICALS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 260 by Market Capitalization
Companies near CENTESSA PHARMACEUTICALS in the global market cap rankings as of May 4, 2026.
Key companies related to CENTESSA PHARMACEUTICALS by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
CENTESSA PHARMACEUTICALS Historical Marketcap From 2021 to 2026
Between 2021 and today, CENTESSA PHARMACEUTICALS's market cap moved from $1.70 Billion to $ 5.74 Billion, with a yearly change of 13.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €5.74 Billion | +121.33% |
| 2025 | €2.59 Billion | -3.85% |
| 2024 | €2.70 Billion | +124.46% |
| 2023 | €1.20 Billion | +139.66% |
| 2022 | €501.17 Million | -70.56% |
| 2021 | €1.70 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of CENTESSA PHARMACEUTICALS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.54 Billion USD |
| MoneyControl | $4.54 Billion USD |
| MarketWatch | $4.54 Billion USD |
| marketcap.company | $4.54 Billion USD |
| Reuters | $4.54 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CENTESSA PHARMACEUTICALS
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as we… Read more